tradingkey.logo
tradingkey.logo
Search

Dr Reddy's Laboratories Ltd

RDY
Add to Watchlist
12.855USD
+0.395+3.17%
Market hours ETQuotes delayed by 15 min
10.70BMarket Cap
16.46P/E TTM

Dr Reddy's Laboratories Ltd

12.855
+0.395+3.17%
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D

Today

+3.17%

5 Days

-3.05%

1 Month

-3.42%

6 Months

-7.18%

Year to Date

-8.44%

1 Year

-7.72%

Key Insights

Dr Reddy's Laboratories Ltd's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 61 out of 156 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 14.73.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Dr Reddy's Laboratories Ltd's Score

Industry at a Glance

Industry Ranking
61 / 156
Overall Ranking
147 / 4490
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Dr Reddy's Laboratories Ltd Highlights

StrengthsRisks
Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 25.74% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 3.85B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 11.81%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 11.81%.
Undervalued
The company’s latest PE is 15.95, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 117.02M shares, decreasing 7.30% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 361.63K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.00.

Analyst Rating

Based on 3 analysts
Buy
Current Rating
14.735
Target Price
+11.38%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Dr Reddy's Laboratories Ltd News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Dr Reddy's Laboratories Ltd Info

Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.
Ticker SymbolRDY
CompanyDr Reddy's Laboratories Ltd
CEOAghanian (Patrick)
Websitehttps://www.drreddys.com/
KeyAI